In the Claims:

Please amend the Claims as shown:

Patent Claims

(currently amended) Peptide compounds of the formula I
(SEQ ID NO: 2)

 $W^1-X^1_nArg X^2 Asp Leu X^3X^4Leu X^5X^6_m-W^2$ I

in which:

X¹, X², X³, X⁴, X⁵, X⁶ each independently of one another are an amino acid residue, the amino acids independently of one another being selected from a group consisting of Ala, Asn, Asp, Arg, Cys, Gln, Glu, Gly, Phe, His, Ile, Leu, Lys, Met, Nle, homo-Phe, Phg, Pro, Ser, Thr, Trp, Tyr or Val, and the amino acids mentioned possibly also being derivatized,

 W^1 is H or Ac,

 W^2 is OH, OR, NHR, NR₂, NH₂,

R is alkyl having 1-6 C atoms and

n, m each independently of one another are a number from 0-15.

- 2. (original) Peptide compounds according to Claim 1, in which X^2 is an amino acid residue which is selected from the group consisting of Thr, Ser, Asp or glycine.
- 3. (original) Peptide compounds according to Claim 1, in which X³ is an amino acid residue selected from the group consisting of Asp, Glu, Arg, Lys, His or Tyr.
- 4. (original) Peptide compounds according to Claim 1, in which X⁴ is an amino acid residue selected from the group consisting of Ser, Tyr, Thr, Gly or Val.
- (currently amended) Peptide compounds according to Claim 1 as in the formula V (SEQ ID NO: 19)

W¹-X¹_nArg Thr Asp Leu Asp Ser Leu Arg X⁶_m-W² V

having the meanings indicated in Claim 1.

6. (currently amended) Peptide compound according to Claim 5 as in formula VI (SEQ ID NO: 20)

W¹-X¹nArg Thr Asp Leu Asp Ser Leu Arg Thr X⁶m-1-W² VI

- 7. (original) Peptide compounds of the formula I or II according to Claims 1 to 6 and their physiologically acceptable salts as medicaments.
- 8. (original) Medicament according to Claim 7 as an inhibitor for the control of disorders which are based on an expression and pathological function of $\alpha_{\nu}\beta_{6}$ integrin receptors.
- 9. (original) Medicament according to Claim 8 for the control of thromboses, cardiac infarct, coronary heart disorders, arteriosclerosis, tumours, osteoporosis, fibrosis, inflammations, infections, psoriasis and for influencing wound healing processes.
- 10. (original) Pharmaceutical preparation comprising at least one medicament according to one of Claims 7 to 9 and, if appropriate, vehicles and/or excipients and, if appropriate, other active compounds.
- 11. (original) Use of peptide compounds according to Claims 1 to 6 and/or their physiologically acceptable salts for the production of a medicament for controlling disorders which are based on an expression and pathological function of $\alpha_{\rm v}\beta_{\rm f}$ integrin receptors.
- 12. (original) Use according to Claim 11 for the production of a medicament for controlling thromboses, cardiac infarct, coronary heart disorders, arteriosclerosis, tumours, osteoporosis, fibrosis, inflammations, infections, psoriasis and for influencing wound healing processes.
- 13. (original) Recombinant DNA comprising a sequence which codes for a peptide section which corresponds to a peptide compound of Claims 1-6.
- 14. (original) Recombinant virus DNA according to Claim 13.
- 15. (original) Virus, characterized in that it possesses a coat protein which has a sequence which corresponds to a peptide compound of Claims 1-6.
- 16. (original) Use of a virus according to Claim 15 for the production of a medicament for controlling disorders which are based on an expression and pathological function of $\alpha_{\nu}\beta_{6}$ integrin receptors.